)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Neurocrine Biosciences (NBIX) investor relations material
Neurocrine Biosciences TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit summary17 Sep, 2025
Evolving R&D strategy and portfolio focus
Shifting R&D strategy to emphasize internal discovery alongside in-licensing, with increased focus on new modalities such as proteins, monoclonal antibodies, and peptides, and prioritizing clinically or genetically validated targets.
Targeting neurology, psychiatry, endocrinology, and immunology, with a central focus on CNS and brain-related diseases.
Portfolio expected to rebalance over time toward 40-50% neurology, 20-30% psychiatry, and 10-20% each for endocrinology and immunology, aiming for higher probability therapeutic areas.
Goal to initiate at least four new phase I, two new phase II, and maintain three phase III programs annually, targeting one new medicine every other year.
Key clinical programs and data updates
NBI-770, an NR2B negative allosteric modulator for major depressive disorder, aims to match ketamine's efficacy with fewer side effects; phase II data expected in October-November, focusing on rapid onset and a 3-4 point MADRS change by day five.
Osavampator, an AMPA potentiator, showed strong efficacy and safety in phase II, with effect sizes up to 0.75 and minimal side effects; phase III trials are ongoing, with primary endpoint at day 56 to capture increasing efficacy over time.
NBI-568 (dracoledine) for schizophrenia demonstrated robust phase II results with a 7.5-point placebo-corrected PANSS improvement and effect size of 0.61; phase III trials are underway with a simplified design and data expected in 2027.
Next-generation VMAT2 inhibitors (NBI-890, NBI-675) are in phase I, aiming for improved compliance and efficacy, including long-acting injectable options.
Commercial performance and outlook
Combined Q2 revenue from CRENESSITY and INGREZZA reached $682 million, a 17% year-over-year increase, with record prescription growth and expanding market share.
Strong advocacy and physician support, along with robust R&D and commercial execution, position the company as a leading neuroscience player.
What specific actions will drive portfolio re-weighting?
How will 770 and osavampator target distinct MDD patient segments?
Quantify 568's competitive advantage from safety/tolerability
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Neurocrine Biosciences earnings date
Q3 202528 Oct, 2025
Next Neurocrine Biosciences earnings date
Q3 202528 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Neurocrine Biosciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for neurological, endocrine, and psychiatric disorders. The company focuses on treatments for conditions such as movement disorders, adrenal diseases, and mental health challenges. Neurocrine Biosciences, Inc. is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage